Begin Your Weight Loss Journey

At Restore, we believe that an active lifestyle is a key ingredient to a fuller, happier life—and that starts with sustaining a healthy weight. Additionally, obesity is associated with many life-threatening diseases, including, but not limited to, diabetes, cancer, hormonal issues, stroke, and cardiovascular disease. We were determined to develop a weight-loss program that was clinically effective, backed by science, deeply personalized and sustainable. The wellness industry is filled with diet and lifestyle fads that claim to deliver weight-loss results, but we were committed to developing a weight management program that was both achievable and aspirational—combining clinically effective components with personalized plans that deliver results.

Qualification for the Weight Management program for those 18 years of age or older is determined by a clinician. Each individual’s body composition, skeletal muscle mass, metabolic health biomarkers/labs, and medical history is analyzed for qualification. Not all candidates will qualify for medication.

At Restore, we’re committed to supporting you on your weight loss journey, whether you qualify for these medications or not. We will work with you to create a personalized plan featuring Restore therapies that support weight loss, including Infrared Sauna, Whole Body Cryotherapy, Lipo + B12 and Vitamin D shots and IV Therapy with L-Carnitine, Trace Minerals, and B vitamins.

Semaglutide is a glucagon-like peptide 1 receptor agonist used to improve metabolic health and support weight loss as an adjunct to lifestyle changes. This active ingredient in FDA-approved medications have become the leading drug in its class due to its proven safety and efficacy.

Tirzepatide is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that is the active ingredient in other FDA-approved drugs for the treatment of type 2 diabetes mellitus. Tirzepatide has also been approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in addition to a reduced calorie diet and increased physical activity.

Possible side effects include: Nausea, diarrhea, vomiting, constipation, mild to moderate abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, belching, hypoglycemia, flatulence, gastroenteritis, loss of lean muscle mass and gastroesophageal reflux disease. Common injection site reactions are characterized by itching and burning at the site of administration with or without thickening of the skin (welting).

Program costs include an intake cost of $100-$150, depending on the studio location and biomarker lab testing. Those who qualify and are deemed eligible candidates for medication by our clinicians will then pay a monthly membership fee of $600-$675, depending on the medication that is prescribed. It is important to note your monthly membership includes medication, ongoing telemedicine visits with a Nurse Practitioner, personalized progress tracking, bi-annual biomarker labs and continuing guidance for your weight loss journey.

It is important to understand that your physiology is unique. Everyone responds differently to medical therapies, and the same is true for semaglutide and tirzepatide. Both tirzepatide and semaglutide have been shown to reduce weight for patients with overweight or obesity in randomized controlled trials. The STEP-1 trial tested the effect of high-dose semaglutide to produce weight loss in people with obesity who do not have diabetes. The results revealed an average 14.9% reduction in body weight from baseline during 68 weeks of treatment with semaglutide 2.4 mg plus a lifestyle intervention, compared with just a 2.4% reduction in the placebo plus lifestyle intervention group. The SURMOUNT-1 trial tested the ability of tirzepatide to produce weight loss in people with obesity who do not have diabetes. During 72 weeks of treatment, people taking tirzepatide at doses of 5, 10, or 15 mg lost an average of 15.0%, 19.5%, and 20.9%, respectively, compared with just 3.1% in people taking a placebo. It is important to note that real-world results from these therapies often differ from the results from controlled clinical trials.

Insurance is not required for the Weight Management Program, as the monthly scheduled telemedicine visits and medications are included in the monthly cost of the Program.

Your eligibility will be based on a consultation with one of our expertly trained clinicians. If approved, we will determine the best way to implement and tailor our Weight Management Program to your needs.